FDA Breakthrough Device Designation to Multi-Cancer Early Detection Test
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that its multi-cancer test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The investigational blood test is in development for the early detection of multiple cancer types in individuals aged